Navigation Links
Cepheid Reports 2009 Second Quarter Results
Date:7/30/2009

n accordance with GAAP and that these measures should only be used to evaluate the company's results of operations in conjunction with the corresponding GAAP measures.

As described above, the company excludes the following items from one or more of its non-GAAP measures when applicable:

Employee share-based compensation expense. These expenses consist primarily of expenses for employee stock options and employee restricted stock under SFAS 123(R). The company excludes employee share-based compensation expenses from its non-GAAP measures primarily because they are non-cash expenses that the company does not believe are reflective of ongoing operating results. Further, as the company applies SFAS 123(R), it believes that it is useful to investors to understand the impact of the application of SFAS 123(R) on its results of operations.

Amortization of purchased intangible assets. The company incurs amortization of purchased intangible assets in connection with acquisitions. The company excludes these items because these expenses are not reflective of ongoing operating results in the period incurred. These amounts arise from the company's prior acquisitions and have no direct correlation to the operation of the company's business.

Restructuring expenses. The company excluded expenses associated with its Q109 restructuring from its results for non-GAAP net loss for the first six months of 2009 and also from its outlook for non-GAAP net loss for fiscal 2009. The company excluded these items as it believes such amounts are non-recurring in nature, and do not have a direct impact on the operation of the company's core business.

Forward-Looking Statements

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the fut
'/>"/>

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
2. Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results
3. Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA
4. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
5. Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association
6. Cepheid Selected as Vendor of Choice by Connecticut Hospital Association Shared Services Program for Molecular MRSA Surveillance Testing
7. Cepheid Reports Record Revenue of $44.8 Million
8. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
9. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
10. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
11. Cepheid Reports Fourth Quarter and Full Year 2008 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ous discovery that grew out of a collaboration bet...ly offer hope to the nearly 10 million Americans w... Also known as hardening of the arteries, periphe...ory problem in which narrowed arteries reduce bloo... red flag for vascular disease, heart attack and s...
(Date:11/25/2009)...ready used to fight rheumatoid arthritis, could he... , WEDNESDAY, Nov. 25 (HealthDay News) -- A dru...d rheumatoid arthritis now also shows some promise...iabetes. , The drug, rituximab (Rituxan), helpe...n, even though the disease had destroyed some of t...
(Date:11/25/2009)...en plagued by neurological symptoms, study finds ...-- Neurological side effects are among the potenti...ular cancer who were treated with cisplatin-based ...y included 1,409 Norwegian men treated for unilate...ok part in a follow-up survey conducted from 1998 ...
(Date:11/25/2009)...GTON,Va.,Nov.25/PRNewswire-USNewswire/--TheAmerica...hCareFraudActof2009,"S.2128,whichisdesignedtosubst...fraudinMedicare.ThebillwasintroducedbySen.GeorgeLe...provisionstheAmericanAssociationforHomecareoutline...tionproposedtoCongressinFebruary.Thoseprovisionsin...
(Date:11/25/2009)... to treat colorectal cancer also can reverse a rar...line therapy for the disease, researchers at Vande..., Mntrier,s disease causes thickening of the stom...ting, as well as anemia and swelling in the feet a...reased risk for gastric cancer. Previously, the on...
Breaking Medicine News(10 mins):Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2
...inska Institutet, our everyday environments are fu...ying degrees when inhaled. Particularly damaging t...rground system in Stockholm, Sweden. "Luckily... My results show that there is every reason to spe...
...ving a toll on the health of the children of the c....// Fast and junk food are the most favoured...ocket money in these joints rather than have a dec...fast foods is resulting in an increase in the inci...
...a tight spot, defending its position against the l...ompany’s best-selling schizophrenia drug, Zyprexa....health risks of the drug, which is being linked to...ence has surfaced, that the company has indeed kep...
...y gatherings to prepare for, the winter season can...pectations and the stresses of holiday events can ... depression is one of the most common illnesses fo...director of the Adult Outpatient Psychiatry Servic...
...ure (USDA) have spent two years ascertaining the p... body composition of infants. The instrument ...em, the size of an infant was tested suitably unde...is team undertook a study of 56 healthy infants, c...
...ation and Authorization of Chemicals, has shifted ...icals to the// manufacturers. The chemical c... safe chemicals for safety of their business. ...roved this legislation on the use of toxic chemica...
Other Medicine News:Health News:Underground Air - Associated With - DNA Damages 2Health News:Child Obesity and Diabetes - A Major Problem in India, 2Health News:Mental Health Expert Offers Tips for a Happier Holiday Season 2Health News:Mental Health Expert Offers Tips for a Happier Holiday Season 3
(Date:11/25/2009)...,, NEWYORK,Nov.25/PRNewswire/--Reportlinker.c...initscatalogue: ,, PainManagement-GlobalTrend...in-Management---Global-Trends.html ,, Widespre...mentclinics,andtheadventofnewdrugshaveacceleratedt...reformsandreimbursementstructurecontinuetoshapedem...
(Date:11/24/2009)...,, BETHESDA,Md.,Nov.24/PRNewswire-Asia/--Chin...leadingindependentAmericanproviderofWestern,health...a,today,announcedthattheCompanywillattendthe21stAn...obeheldDecember1-2,2009,atthe,NewYorkPalaceHotel. ...:30amETonTuesday,December1,2009,andholdone-on-one...
(Date:11/24/2009)...,, SANDIEGO,Nov.24/PRNewswire-FirstCall/--Ana...aythatitwillpresentatthe21stAnnualPiperJaffrayHeal...EST(6:00a.m.PST).TheconferenceisbeingheldatTheNewY...fExecutiveOfficerofAnadys,willprovideanoverviewofA...A773. ,, Thecorporatepresentationwillbesimultan...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Chindex International to Present at Piper Jaffray Health Care Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2MHPA Leading Association Representing Medicaid Health Plans Issues Statement on Proposed California SCHIP Elimination 47534 1MHPA Leading Association Representing Medicaid Health Plans Issues Statement on Proposed California SCHIP Elimination 47534 2IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 1IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 2IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 3IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 4IMPACT Study Showed Longer Valcyte 28R 29 28valganciclovir hydrochloride tablets 29 Treatment Demonstrated Better Protection Against Cytomegalovirus 4505 5Nuvilex Launches Video Marketing Campaign 47528 1Nuvilex Launches Video Marketing Campaign 47528 2Nuvilex Launches Video Marketing Campaign 47528 3
... Activity and Long-Term Tumor Re... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) to...l data,showing that Trubion,s TRU-016 has potent a...rm tumor eradication in a human tumor xenograft mo...sponses. TRU-016 is Trubion,s,proprietary CD37-tar...
...ential New Front-Line Treatment ...2 Genzyme Corp.,(Nasdaq: GENZ ) reported prelimi...se 2 study examining the safety and effectiveness ...eviously untreated, older adult,patients with acut...enefit,from conventional "7+3" anthracycline plus ...
Other Medicine Technology:Trubion Announces Presentation of Positive TRU-016 Data at ASCO 2Trubion Announces Presentation of Positive TRU-016 Data at ASCO 3Trubion Announces Presentation of Positive TRU-016 Data at ASCO 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 8
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
...reference laboratory and a worldwide leader in inn...offers an extensive test menu of highly complex an...thology. Owned by the University of Utah, ARUP Lab...ation's university teaching hospitals and children...
Medicine Products: